FDA supplemental approval: Hydrocodone Bitartrate AND Acetaminophen (REMS)

AI Summary

The FDA approved a supplemental REMS (Risk Evaluation and Mitigation Strategy) for hydrocodone bitartrate and acetaminophen tablets in four dose combinations (2.5 mg, 5 mg, 7.5 mg, and 10 mg hydrocodone with 325 mg acetaminophen) on 18 June 2026. This is a regulatory action governing risk management requirements, not a report of clinical trial efficacy or safety data.

Plain-language summary

FDA supplemental approval of a Risk Evaluation and Mitigation Strategy (REMS) for hydrocodone bitartrate and acetaminophen tablets across multiple dose strengths.

Study design

As stated by the source record.

Reported figures

Quoted from the source exactly as published.

Clinical bottom line

This approval establishes regulatory requirements for risk mitigation (REMS) governing the prescribing, dispensing, and use of these combination opioid-acetaminophen tablets. Clinicians must comply with the REMS program terms when considering these products, though this record does not report clinical efficacy or comparative safety evidence.

Caveats

• This regulatory record does not contain clinical trial results, efficacy data, or comparative safety evidence
• The specific REMS requirements (e.g., prescriber certification, patient counseling, healthcare provider agreements) are not detailed in this record
• No information on what prompted or changed in the REMS program for this supplement
• Record does not indicate whether this represents a new REMS or modification to an existing one

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.